| Index | — | P/E | 39.10 | EPS (ttm) | 0.86 | Insider Own | — | Shs Outstand | 877.35M | Perf Week | -0.18% |
| Market Cap | 29.51B | Forward P/E | 21.56 | EPS next Y | 1.56 | Insider Trans | -9.00% | Shs Float | 509.79M | Perf Month | -5.56% |
| Enterprise Value | 39.41B | PEG | 3.48 | EPS next Q | 0.34 | Short Float | 8.01% | Perf Quarter | -20.00% | ||
| Income | 691.00M | P/S | 0.99 | EPS this Y | 23.72% | Short Ratio | 5.29 | Perf Half Y | -23.90% | ||
| Sales | 29.94B | P/B | 1.55 | EPS next Y | 4.82% | ROA | 1.76% | Short Interest | 40.82M | Perf YTD | -19.93% |
| Book/sh | 21.74 | P/C | 11.02 | EPS next 5Y | 11.22% | ROE | 5.45% | 52W High | 50.88 -33.90% | Perf Year | — |
| Cash/sh | 3.05 | P/FCF | 14.56 | EPS past 3/5Y | — | ROIC | 4.04% | 52W Low | 31.37 7.20% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | 14.97 | Sales past 3/5Y | 9.85% — | Gross Margin | 25.02% | Volatility | 3.86% 3.15% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 1.32 | EPS Y/Y TTM | — | Oper. Margin | 6.07% | ATR (14) | 1.19 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.61 | Sales Y/Y TTM | — | Profit Margin | 2.31% | RSI (14) | 45.37 | Recom | 2.15 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.33 | EPS Q/Q | 51.52% | SMA20 | -3.09% | Beta | 0.55 | Target Price | 44.20 |
| Payout | 13.89% | Debt/Eq | 0.66 | Sales Q/Q | 11.60% | SMA50 | -2.51% | Rel Volume | 0.96 | Prev Close | 32.12 |
| Employees | 45,000 | LT Debt/Eq | 0.66 | Earnings | Nov 04 | SMA200 | -15.08% | Avg Volume | 8.62M | Price | 33.63 |
| IPO Date | Dec 17, 2025 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 41.87% 2.21% | Net Debt/EBITDA | 3.76 | Volume | 8,307,318 | Change | 4.70% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Reiterated | Mizuho | Outperform | $48 → $45 |
| Oct-09-26 | Reiterated | Barclays | Overweight | $45 → $43 |
| Sep-25-26 | Reiterated | UBS | Buy | $48 → $43 |
| Aug-27-26 | Reiterated | BTIG | Buy | $50 → $55 |
| Aug-06-26 | Reiterated | Robert W. Baird | $45 → $42 | |
| Aug-06-26 | Reiterated | Stifel Nicolaus | $50 → $45 | |
| Aug-06-26 | Reiterated | BMO Capital | Outperform | $54 → $47 |
| Aug-06-26 | Reiterated | Deutsche Bank | $42 → $37 | |
| Aug-06-26 | Reiterated | Evercore ISI Group | Outperform | $55 → $39 |
| Aug-06-26 | Reiterated | RBC Capital | Outperform | $47 → $46 |
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing medical and surgical items. This encompasses essentials like wound care treatments, examination gloves, skin and incontinence products, sanitation supplies, various textiles, hand sanitizers, durable medical equipment (DME), patient-specific plastic goods, and decolonization and infection control solutions. The Surgical Solutions category delivers comprehensive product lines for operating rooms and perioperative settings. Offerings range from surgical procedure trays, drapes, and gowns to personal protective equipment (PPE), sterile wraps, various surgical instruments, specialized surgeon's gloves, complete procedure kits, and orthopedic implants. Finally, Laboratory and Diagnostics supplies critical solutions for clinical testing and analysis. This includes point-of-care testing devices, analytical instruments, laboratory consumables, advanced diagnostic equipment, vital signs monitoring systems, and products for anatomic pathology and phlebotomy. The Supply Chain Solutions segment is responsible for sourcing and distributing a diverse portfolio of third-party products, including those from well-known national brands. Beyond distribution, this segment offers comprehensive logistics and supply chain optimization services to clients both domestically and internationally. These optimization services encompass strategic consulting, outsourced management of warehousing and technology, specialized "put-away-ready" packaging, third-party logistics (3PL), inventory rationalization strategies, and efficient route planning. Established in 1966, Medline Inc. maintains its headquarters in Northfield, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|---|
| Total Revenue | 29,939 | 28,432 | 25,507 | 23,231 | — | |
| Cost of Goods Sold Incl. D&A | 22,447 | 20,914 | 19,216 | 18,008 | — | |
| Gross Profit | 7,492 | 7,518 | 6,291 | 5,223 | — | |
| Selling, General and Administrative Excl. Other | 4,904 | 4,524 | 4,041 | 3,807 | — | |
| Research and Development | 0 | 0 | 67 | 60 | — | |
| Other Operating Expense | 772 | 782 | -42 | -88 | — | |
| Operating Income | 1,816 | 2,212 | 2,225 | 1,444 | — | |
| Interest Expense | 727 | 812 | 1,309 | 1,375 | — | |
| Unusual Expense | — | — | — | — | — | |
| Non-Operating Income (Expense) | -12 | -152 | 330 | 195 | — | |
| Net Income Before Taxes | 1,077 | 1,248 | 1,246 | 264 | — | |
| Income Taxes | 197 | 91 | 46 | 30 | — | |
| Consolidated Net Income | 691 | 1,159 | 1,200 | 234 | — | |
| Net Income From Continuing Operations | 880 | 1,157 | 1,200 | 234 | — | |
| Net Income | 691 | 1,159 | 1,200 | 234 | — | |
| EPS (Recurring) | 0.86 | 1.43 | 1.52 | 0.30 | — | |
| EPS (Basic, Before Extraordinaries) | 0.86 | 1.43 | 1.52 | 0.30 | — | |
| EPS (Diluted) | 0.86 | 1.43 | 1.52 | 0.30 | — | |
| EBITDA | 2,633 | 2,259 | 3,532 | 2,590 | — | |
| Other After Tax Adjustments | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | |
| Price To Earnings Ratio | 39.10 | 29.37 | — | — | — | |
| Price To Sales Ratio | 0.96 | 1.20 | — | — | — | |
| Gross Margin | 25.02 | 26.44 | 24.66 | 22.48 | — | |
| Operating Margin | 6.07 | 7.78 | 8.72 | 6.22 | — | |
| Net Margin | 2.31 | 4.08 | 4.70 | 1.01 | — | |
| Shares Outstanding | 857 | 812 | 787 | 787 | — | |
| Market Capitalization | 28,821 | 34,104 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| GIC Private Ltd | 10% Owner | Oct 08 '26 | Sale | 35.15 | 7,816,987 | 274,767,093 | 69,408,506 | Oct 13 |
| GIC Private Ltd | 10% Owner | Oct 06 '26 | Sale | 35.05 | 9,272,000 | 324,983,600 | 16,453,806 | Oct 06 |
| GIC Private Ltd | 10% Owner | Oct 05 '26 | Sale | 35.78 | 1,688,690 | 60,421,328 | 18,542,793 | Oct 06 |
| GIC Private Ltd | 10% Owner | Oct 02 '26 | Sale | 34.60 | 9,717,940 | 336,239,300 | 20,231,483 | Oct 06 |
| GIC Private Ltd | 10% Owner | Aug 14 '26 | Sale | 35.80 | 100,000 | 3,580,000 | 22,802,482 | Aug 17 |
| GIC Private Ltd | 10% Owner | Aug 13 '26 | Sale | 35.80 | 1,500,000 | 53,700,000 | 22,902,482 | Aug 17 |
| GIC Private Ltd | 10% Owner | Aug 07 '26 | Sale | 35.58 | 590,284 | 21,002,305 | 24,402,482 | Aug 11 |
| GIC Private Ltd | 10% Owner | Aug 06 '26 | Sale | 35.33 | 271,994 | 9,609,548 | 24,992,766 | Aug 07 |
| GIC Private Ltd | 10% Owner | Aug 05 '26 | Sale | 35.60 | 1,976,618 | 70,361,899 | 25,264,760 | Aug 07 |
| BCP 8 Holdings Mozart Manager L.L.C. | 10% Owner | May 28 '26 | Sale | 36.54 | 33,317,824 | 1,217,349,994 | 1,539 | Jun 01 |
| Carlyle Group Inc. | 10% Owner | Mar 10 '26 | Sale | 41.00 | 26,105,840 | 1,070,339,440 | 127,567,724 | Mar 12 |
| BCP 8 Holdings Mozart Manager L.L.C. | 10% Owner | Mar 10 '26 | Sale | 40.51 | 27,852,986 | 1,128,268,756 | 1,539 | Mar 12 |
| Carlyle Group Inc. | 10% Owner | Dec 18 '25 | Sale | 29.00 | 19,136,333 | 554,953,657 | 145,924,924 | Dec 22 |
| Mozart Aggregator II LP | 10% Owner | Dec 18 '25 | Sale | 18.71 | 20,417,040 | 381,911,076 | 72,372,632 | Dec 22 |